盐酸氨溴索对慢性阻塞性肺疾病患者急性期血清白细胞介素8及白细胞介素18的影响

目的 研究盐酸氨溴索对慢性阻塞性肺疾病(COPD)急性加重期白细胞介素8(IL)-8、IL-18的影响.方法 选择2007年11月至2009年11月住院的慢性阻塞性肺疾病患者82例,入院时均为急性加重期,肺功能中度.完全随机分为观察组50例,对照组32例.观察组在常规治疗基础上加用盐酸氨溴索注射液30 mg+5%葡萄糖注射液250 ml静脉滴注,2次/d,疗程14 d;对照组仅给予常规治疗,疗程14 d.分别观察2组治疗前后血清IL-8、IL-18水平.结果 对照组及观察组治疗后IL-8、IL-18水平分别为(139.81±42.38)ng/L、(64.2±19.6)ng/L及(89.27±30.68)ng/L、(49.8±17.9)ng/L.2组治疗后血清IL-8、IL-18水平均低于治疗前,差异具有统计学意义(P＜0.05);观察组治疗后血清IL-8、IL-18水平低于对照组,差异具有统计学意义(P＜0.05).结论 盐酸氨溴索可以抑制COPD患者血清IL-8、IL-18的释放,可能有一定的肺保护和治疗作用.

Abstract：

Objective To study the effect of ambroxo1 on interleukin (IL)-8, IL-18 in chronic obstructive pulmonary disease (COPD). Methods Eighty-two patients with acute exacerbation of chsonic obstructive pulmonary disease (AECOPD) between 2007 and 2009 were enrolled, according to the guidelines for COPD treatment. All patients were in acute period with middle level lung dysfunction. They were divided into two groups: conventional therapy (n = 32 ), conventional and interferential therapy ( n = 50). The treatment group was given conventional therapy plus ambroxol for 14 days. The levels of IL-8,IL-18 in serum before-and-after therapy in two groups were observed. Results The level of IL-8, IL-18 in serum of two groups after therapy was lower than that before therapy (P ＜0.05). In the group of conventional plus interferential theraphy,the level of IL-8 ,IL-18 in serum after therapy were lower than that of conventional therapy ( P ＜ 0.05). Conclusion Ambroxol can inhibit the release of IL-8,IL-18 in serum of COPD patients.

The effects of ambroxol hydrochloride on serum Interleukin-8, Interleukin-18 in patients with acute exacerbation of chronic obstructive lung disease

Objective To study the effect of ambroxo1 on interleukin (IL)-8, IL-18 in chronic obstructive pulmonary disease (COPD). Methods Eighty-two patients with acute exacerbation of chsonic obstructive pulmonary disease (AECOPD) between 2007 and 2009 were enrolled, according to the guidelines for COPD treatment. All patients were in acute period with middle level lung dysfunction. They were divided into two groups: conventional therapy (n = 32 ), conventional and interferential therapy ( n = 50). The treatment group was given conventional therapy plus ambroxol for 14 days. The levels of IL-8,IL-18 in serum before-and-after therapy in two groups were observed. Results The level of IL-8, IL-18 in serum of two groups after therapy was lower than that before therapy (P ＜0.05). In the group of conventional plus interferential theraphy,the level of IL-8 ,IL-18 in serum after therapy were lower than that of conventional therapy ( P ＜ 0.05). Conclusion Ambroxol can inhibit the release of IL-8,IL-18 in serum of COPD patients.